Ribomic Inc.
Records under this name other than the patents Ribomic Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 4 patents it holds.
Showing 1 to 10 of 10 · Back to Ribomic Inc.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,128,934 | Method for Treatment or Prevention of Disease Associated with Functional Disorder of Regulatory T Cell Formerly held Term ended Term ended Nov 14, 2026 · High confidence | Term ended | Term ended Nov 14, 2026 | High confidence |
| US 8,637,656 | Nucleic acid capable of binding to immunoglobulin G and use thereof Lapsed on the fee record Ended Jan 28, 2026 · From the USPTO record | Lapsed on the fee record | Ended Jan 28, 2026 | From the USPTO record |
| US 9,567,589 | NGF aptamer and application thereof Lapsed on the fee record Ended Feb 14, 2025 · From the USPTO record | Lapsed on the fee record | Ended Feb 14, 2025 | From the USPTO record |
| US 9,175,292 | Aptamer for NGF and Use Thereof Lapsed on the fee record Ended Nov 3, 2023 · High confidence | Lapsed on the fee record | Ended Nov 3, 2023 | High confidence |
| US 10,260,070 | Aptamer for NGF and Use Thereof Lapsed on the fee record Ended Apr 16, 2023 · High confidence | Lapsed on the fee record | Ended Apr 16, 2023 | High confidence |
| US 9,506,070 | Aptamer Against Midkine and Applications Thereof Formerly held Lapsed on the fee record Ended Nov 29, 2020 · High confidence | Lapsed on the fee record | Ended Nov 29, 2020 | High confidence |
| US 8,080,649 | Aptamer against midkine and use thereof Lapsed on the fee record Ended Dec 20, 2019 · From the USPTO record | Lapsed on the fee record | Ended Dec 20, 2019 | From the USPTO record |
| US 9,012,420 | Aptamer for Chymase, and Use Thereof Lapsed on the fee record Ended Apr 21, 2019 · High confidence | Lapsed on the fee record | Ended Apr 21, 2019 | High confidence |
| US 8,772,259 | Aptamer to FGF2 and use thereof Lapsed on the fee record Ended Jul 8, 2018 · From the USPTO record | Lapsed on the fee record | Ended Jul 8, 2018 | From the USPTO record |
| US 8,716,230 | Methods for Treatment or Prevention of Diseases Associated with Functional Disorder of Regulatory T Cells Formerly held Lapsed on the fee record Ended May 6, 2018 · Medium confidence | Lapsed on the fee record | Ended May 6, 2018 | Medium confidence |